We have previously reported that plasma CXCL10 is associated with disease activity in early RA [20], and others have shown that serum CXCL10 may be used to predict treatment response in RA patients treated with anti-TNF therapy [21]. This evidence concerns the gene CXCL10 and rheumatoid arthritis.